Search results for "vaccine."

showing 10 items of 789 documents

Controversies surrounding human papilloma virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment.

2009

Head & Neck Cancer (HNC) represents the sixth most common malignancy worldwide and it is historically linked to well-known behavioural risk factors, i.e., tobacco smoking and/or the alcohol consumption. Recently, substantial evidence has been mounting that Human Papillomavirus (HPV) infection is playing an increasing important role in oral cancer. Because of the attention and clamor surrounding oral HPV infection and related cancers, as well as the use of HPV prophylactic vaccines, in this invited perspective the authors raise some questions and review some controversial issues on HPV infection and its role in HNC, with a particular focus on oral squamous cell carcinoma. The problematic def…

Oncologymedicine.medical_specialtyPathologyMalignancyPapillomavirus VaccinesInternal medicineHumansMedicineHuman papilloma virus infectionHPV infection;oral cancer;Papillomavirus VaccinesMouth neoplasmbusiness.industryTransmission (medicine)Papillomavirus InfectionsHPV infectionvirus diseasesCancerGenetic Therapyoral cancerPrognosismedicine.diseaseCombined Modality Therapyfemale genital diseases and pregnancy complicationsstomatognathic diseasesOncologyOtorhinolaryngologyOtorhinolaryngologyHead and Neck NeoplasmsHPV infectionCommentaryMouth Neoplasmsbusiness
researchProduct

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

2014

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evalua- 15 tion to overcome treatment failure in patients experiencing recurrence. Areas covered: Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer pa…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryTreatment failureInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientTreatment FailureBiologyOvarian Neoplasmsantibody cancer vaccines cell transfer immune system immunotherapy ovarian cancer recurrence treatment strategiesPharmacologyChemotherapybusiness.industryTreatment optionsImmunotherapymedicine.diseaseClinical trialRecurrent Ovarian CancerImmunologyFemaleImmunotherapyHuman medicineNeoplasm Recurrence LocalOvarian cancerbusinessEngineering sciences. TechnologyExpert Opinion on Biological Therapy
researchProduct

The regulatory landscape for actively personalized cancer immunotherapies

2013

Oncologymedicine.medical_specialtybusiness.industryBiomedical EngineeringCancerBioengineeringmedicine.diseaseCancer VaccinesApplied Microbiology and BiotechnologySocial Control FormalDrug developmentNeoplasmsInternal medicineImmunologyBiomarkers TumormedicineHumansMolecular MedicineImmunotherapyPrecision MedicinebusinessBiotechnologyNature Biotechnology
researchProduct

New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge

1999

Virus-like particles generated by the heterologous expression of virus structural proteins are able to potentiate the immunogenicity of foreign epitopes presented on their surface. In recent years epitopes of various origin have been inserted into the core antigen of hepatitis B virus (HBV) allowing the formation of chimaeric HBV core particles. Chimaeric core particles carrying the 45 N-terminal amino acids of the Puumala hantavirus nucleocapsid protein induced protective immunity in bank voles, the natural host of this hantavirus. Particles applied in the absence of adjuvant are still immunogenic and partially protective in bank voles. Although a C-terminally truncated core antigen of HBV…

OrthohantavirusHantavirus InfectionsRecombinant Fusion ProteinsvirusesGenetic VectorsMolecular Sequence DataBioengineeringBiologymedicine.disease_causeRecombinant virusApplied Microbiology and BiotechnologyEpitopeVirusEpitopesVirus-like particlemedicineAnimalsHumansAmino Acid SequenceAntigens ViralHantavirusHepatitis B virusVaccines SyntheticBase SequenceArvicolinaeImmunogenicityViral VaccinesGeneral MedicineHepatitis B Core AntigensVirologyMolecular biologyHBcAgPlasmidsBiotechnologyJournal of Biotechnology
researchProduct

Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model

1998

Abstract Hantaviruses are rodent-born agents which are pathogenic in humans causing haemorrhagic fever with renal syndrome or hantavirus pulmonary syndrome. To induce a protective immunity against a European hantavirus (Puumala) we constructed chimaeric hepatitis B virus (HBV) core particles carrying defined fragments of the Puumala virus nucleocapsid protein. After immunisation of bank voles, the natural host of Puumala virus, with core particles possessing an insertion of the N-terminal part of Puumala virus nucleocapsid protein, four of five animals were protected against subsequent virus challenge. The results show that the major protective region of the nucleocapsid protein is located …

OrthohantavirusHantavirus InfectionsRecombinant Fusion Proteinsvirusesmedicine.disease_causeVirusVirus-like particlemedicineAnimalsNucleocapsidHantavirusHepatitis B virusHantavirus pulmonary syndromeGeneral VeterinaryGeneral Immunology and MicrobiologybiologyArvicolinaePublic Health Environmental and Occupational Healthvirus diseasesViral Vaccinesbiology.organism_classificationHepatitis B Core AntigensVirologyInfectious DiseasesHepadnaviridaeMolecular MedicinePuumala virusBunyaviridaeVaccine
researchProduct

An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive…

2004

AbstractPreviously, we have demonstrated that hepatitis B virus (HBV) core particles tolerate the insertion of the amino-terminal 120 amino acids (aa) of the Puumala hantavirus nucleocapsid (N) protein. Here, we demonstrate that the insertion of 120 amino-terminal aa of N proteins from highly virulent Dobrava and Hantaan hantaviruses allows the formation of chimeric core particles. These particles expose the inserted foreign protein segments, at least in part, on their surface. Analysis by electron cryomicroscopy of chimeric particles harbouring the Puumala virus (PUUV) N segment revealed 90% T = 3 and 10% T = 4 shells. A map computed from T = 3 shells shows additional density splaying out …

OrthohantavirusHepatitis B virusCryo-electron microscopyHantavirus InfectionsRecombinant Fusion ProteinsVirulenceCross Reactions030312 virologyAntibodies Viralmedicine.disease_causeCore antigenMice03 medical and health sciencesVirologymedicineAnimals030304 developmental biologyHantavirusNucleocapsid proteinchemistry.chemical_classificationHepatitis B virusMice Inbred BALB C0303 health sciencesbiologyCryoelectron MicroscopyViral VaccinesNucleocapsid ProteinsVirus-like particlesbiology.organism_classificationHepatitis B Core AntigensVirology3. Good healthAmino acidMice Inbred C57BLchemistrybiology.proteinFemalePuumala virusAntibodyHantavirus InfectionHantavirusVirology
researchProduct

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or…

2005

Hepatitis B virus (HBV) core particles carrying the amino-terminal 120 amino acids (aa) of the nucleocapsid (N) protein of the hantaviruses Dobrava, Hantaan or Puumala have been demonstrated to be highly immunogenic in mice when complexed with adjuvants. Here we demonstrate that even without adjuvant, these chimeric particles induced high-titered, and strongly cross-reactive N-specific antibody responses in BALB/c and C57BL/6 mice. The induced N-specific antibodies represented all IgG subclasses. Pre-existing core-specific antibodies did not abrogate the induction of an N-specific immune response by a hantavirus N insert presented on core particles. Therefore, chimeric core particles should…

Orthohantavirusmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySaccharomyces cerevisiaeCross Reactionsmedicine.disease_causeAntibodies ViralVirusMiceOrthohepadnavirusAdjuvants ImmunologicmedicineEscherichia coliAnimalsImmunization ScheduleHantavirusHepatitis B virusMice Inbred BALB CVaccines SyntheticGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesNucleocapsid Proteinsbiology.organism_classificationVirologyHepatitis B Core AntigensMice Inbred C57BLInfectious DiseasesHepadnaviridaeImmunoglobulin Gbiology.proteinMolecular MedicineFemaleAntibodyCarrier ProteinsAdjuvantPlasmidsVaccine
researchProduct

Fetal Calf Serum-Free Generation of Functionally Active Murine Dendritic Cells Suitable for In Vivo Therapeutic Approaches

2000

Standard protocols to generate mouse dendritic cells (DC) generally use culture medium supplemented with fetal calf serum; however, reinjection in vivo of DC cultured in fetal calf serum results in priming to xenogeneic proteins that clearly limits the use of such DC. We therefore established a fetal calf serum-free culture system for the generation of murine DC from bone marrow precursors. DC can be generated fetal calf serum-free using RPMI supplemented with 1.5% syngeneic mouse serum. Although the yield of DC grown under fetal calf serum-free conditions was somewhat lower than that of the standard culture, large numbers of DC could be generated without the exposure to xenogeneic proteins…

OvalbuminReceptors Antigen T-CellBone Marrow CellsCell CountMice Inbred StrainsMice TransgenicDermatologyBiologyDermatitis ContactBiochemistryin vivo therapeutic DC approachesAndrologyMiceImmune systemCell MovementIn vivoAnimalsdendritic cell development cellsMolecular BiologyCD86DC vaccinesFetusfetal calf serum-free culture conditions for DCCD40Tumor Necrosis Factor-alphaStem CellsDendritic CellsCell BiologyDendritic cellFetal BloodCulture MediaPhenotypeCell cultureImmunologybiology.proteinCattleCell DivisionCD80Interleukin-1Journal of Investigative Dermatology
researchProduct

An international perspective on hospitalized patients with viral community-acquired pneumonia

2019

Background Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results 553 (14.9%) patients with CAP underwent nasal swab. Viral CA…

PNEUMONIAMaleMultivariate analysisInternationalityPCV13 pneumococcal conjugate vaccineDatabases FactualHospitalized patientsmedicine.medical_treatmentvirusesCAD coronary artery diseaseTesting030204 cardiovascular system & hematologyMRSA methicillin resistant Staphylococcus aureusPneumònia adquirida a la comunitatRT-PCR reverse transcriptase polymerase chain reactionchemistry.chemical_compound0302 clinical medicineCommunity-acquired pneumoniaTaverne80 and overCommunity-Acquired InfectionViral030212 general & internal medicineProspective StudiesAged 80 and overRIDT rapid influenza diagnostic testCAP community-acquired pneumoniaRSV Respiratory Syncytial virusMiddle AgedICU intensive care unitCommunity-Acquired InfectionsHospitalizationNasal SwabInfectious diseasesFemaleViral swabHumanOseltamivirmedicine.medical_specialtyLogistic ModelCommunity-acquired pneumoniaViral pneumoniaCommunity acquired pneumonia; Influenza; Oseltamivir; Testing; Viral pneumonia; Viral swab; Aged; Aged 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases Factual; Female; Hospitalization; Humans; Influenza Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia Viral; Prospective StudiesPneumonia ViralAdmissionSettore MED/10 - Malattie Dell'Apparato RespiratorioInfluenzavirusAntiviral AgentsVirusArticleMedication AdherenceHMPV human MetapneumovirusDatabases03 medical and health sciencesLRTI lower respiratory tract infectionOseltamivirInternal medicineInfluenza HumanInternal MedicinemedicineInfluenza virusesHumansHIV Human Immunodeficiency virusPPSV23 pneumococcal polysaccharide vaccineIn patientFactualAgedMechanical ventilationAntiviral AgentCross-Sectional Studiebusiness.industryFEV1 forced expiratory volume in one secondGLIMP global initiative for methicillin-resistant Staphylococcus aureus pneumoniaESBL extended-spectrum beta-lactamasesPneumoniamedicine.diseaseInfluenzaCommunity acquired pneumoniaCI confidence intervalOR odds ratioCross-Sectional StudiesLogistic ModelschemistryCOPD chronic obstructive pulmonary diseasebusinessCommunity acquired pneumonia ; Influenza ; Oseltamivir ; Testing ; Viral pneumonia ; Viral swab
researchProduct

Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-anal…

2016

ABSTRACT Low measles, mumps and rubella (MMR) immunization levels in European children highlight the importance of identifying determinants of parental vaccine uptake to implement policies for increasing vaccine compliance. The aim of this paper is to identify the main factors associated with partial and full MMR vaccination uptake in European parents, and combine the different studies to obtain overall quantitative measures. This activity is included within the ESCULAPIO project, funded by the Italian Ministry of Health. ORs and CIs were extracted, sources of heterogeneity explored and publication bias assessed. Forty-five papers were retrieved for the qualitative study, 26 of which were i…

ParentsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyMeasles-Mumps-Rubella Vaccinedeterminant; measles; mumps and rubella; parents; uptake; vaccine; Immunology and Allergy; Immunology; PharmacologyImmunologyReviewdeterminantSettore MED/42 - Igiene Generale E ApplicataMMR vaccineRubellaMeasles03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsHumansmeaslesmeasleImmunology and AllergyMedicinemumps and rubella030212 general & internal medicineMumpsRubellaPharmacologyPracticebusiness.industryHealth KnowledgeVaccinationPublication biasPatient Acceptance of Health Caremedicine.diseaseEuropeVaccinationparentdeterminant; measles; mumps and rubella; parents; uptake; vaccine; Europe; Health Knowledge Attitudes Practice; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Patient Acceptance of Health Care; Rubella; Vaccination; ParentsAttitudesuptakeMeta-analysisMarital statusbusinessMeasles-Mumps-Rubella VaccineDemographyHuman Vaccines & Immunotherapeutics
researchProduct